Objective: This study investigates the role of serum copeptin levels measured in the early post-traumatic period (first 24 hours) in adult patients with multiple blunt trauma (MBT) in determining trauma severity and the predicting prognosis. Materials and Methods:This prospective cross-sectional study was enrolled 78 consecutive adult patients with MBT and 72 age-and sex-matched healthy controls with no acute traumatic injuries. The serum level of copeptin was assessed in all individuals were included in the study.Results: No significant difference was observed between the patients with MBT and the control group in serum copeptin levels (3.13±6.10 vs. 3.90±6.82 and p=0.468). In addition, no statistically significant correlation was found between serum copeptin levels and age, revised trauma score (RTS), injury severity score (ISS), and Glasgow Coma scale values in patients with MBT. Additionally, no significant was observed difference between the hospitalized and discharged patients from the emergency department (ED) in terms of serum copeptin levels (1.72±3.05 vs. 1.95±3.50 and p=0.783). Conclusion:In our study, trauma scores such as high RTS and low ISS values help determine the discharge from the ED in patients with multitrauma. However, we concluded that the serum copeptin level in these patients was not valuable in predicting trauma severity and prognosis in the early post-trauma period (in the first 24 hours).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.